Home > Press > Arrowhead Closes Underwritten Offering with Gross Proceeds of $120 Million
 |
Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that on February 24, 2014 it closed the previously announced underwritten offering of 6,325,000 shares of common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 825,000 additional shares. The offering was priced at $18.95 per share and the company received gross proceeds of approximately $120 million, before deducting underwriting discounts, commissions, and other offering expenses payable by the company. Jefferies LLC, Barclays Capital Inc., and Deutsche Bank Securities acted as joint book-runners for the offering. Piper Jaffray & Co. acted as lead manager for the offering and Trout Capital acted as a financial advisor to the Company.
Arrowhead Closes Underwritten Offering with Gross Proceeds of $120 Million
Pasadena, CA | Posted on February 24th, 2014####
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead's pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.
For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
For more information, please click here
Contacts:
Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
The Trout Group
Lauren Glaser
646-378-2972
Copyright © Arrowhead Research Corporation
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
| Related News Press |
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||